Increasing evidence suggests that KRAS mutation preferentially induces an immunosuppressive TME by promoting the expression of immunomodulatory factors of tumour cells, such as transforming growth factor-β, interleukin-6, and interleukin-10203. The gene discussed is KRAS; the disease is neoplasm.